Regeneron CEO: Antibody Treatment Not A Proven Cure

Regeneron's CEO Leonard Schleifer discussed the company's antibody cocktail as a potential COVID-19 treatment. He emphasized that President Trump's case is not strong evidence due to its singular nature. Fewer than 10 people, including Trump, accessed the drug outside of a study. Schleifer highlighted the importance of larger clinical trials to determine the drug's efficacy. Regeneron is seeking FDA emergency use authorization based on preliminary evidence.

What does the text imply about the evidence needed for the drug's effectiveness?

Why does the company believe it is an appropriate time to seek emergency use authorization?